Navigation Links
Stereotaxis Reports Record First Quarter Orders
Date:5/6/2008

nference, HRS, with very strong momentum."

After adjustment for one order, which the Company elected to take out of backlog due to delays in funding for an overseas project, and for systems recognized to revenue in the first quarter, at March 31, 2008, purchase orders and other commitments for Stereotaxis systems totaled approximately $66 million, including approximately $13 million of new orders received during the quarter. Of the new orders, approximately $1.5 million were for the Odyssey system. The Company reported orders of $10.6 million in the first quarter of 2007. The Company does not include orders for disposables, service, or other accessories in its backlog data. These orders or commitments are subject to contingencies that are outside the Company's control and may be revised, modified or cancelled. Competitive efforts continue to have little or no impact on the Company's order flow or conversion of backlog to revenue.

"Clinicians have now performed approximately 15,000 procedures using our Niobe system. Most importantly, our major adverse event rate in electrophysiology stands at an impressive 0.1%. We believe this safety record is unsurpassed, by far, compared with both manual and competitive robotic procedures, and is supported by a substantial body of almost 90 peer-reviewed publications," added Mr. Hogg. "We are confident in our belief that well- informed physicians and their patients will invariably seek out the safer alternative."

"We have also developed tremendous interest in our Odyssey system, and during the first quarter we added approximately $1.5 million in Odyssey orders to our backlog," said Mr. Hogg. "It appears as though we will far exceed our original goal of 20 orders for the Odyssey system during 2008. We believe that the Odyssey platform, acting as the information and networking hub for the EP lab, can enable clinicians to improve efficiency and efficacy, by making it possible to consolidate and better manage info
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Stereotaxis to Present at the Deutsche Bank 33rd Annual Health Care Conference
2. Stereotaxis Niobe Magnetic Navigation Systems Perform Approximately 15,000 Cases
3. Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe
4. Stereotaxis Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
5. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
6. Stereotaxis Receives $20 Million in Additional Loan Commitments
7. Stereotaxis Provides Fourth Quarter 2007 Revenue Outlook
8. Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
9. Stereotaxis Showcases Interventional Cardiology Capabilities of Niobe Magnetic Navigation System
10. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
11. Kaiser Foundation Health Plan and Hospitals Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... “ Francis Drake Eyewear ” was ... monthly Biz Report, which reviews and features the latest ... host of NewsWatch and technology expert, conducted the review ... can save users hundreds of dollars while still looking ... company creates fashion-forward glasses that are both stylish and ...
(Date:9/18/2014)... 2014 9Lover.com, an internationally well-known designer ... launched a big promotion for its maternity wedding outfits. ... buy discounted maternity wedding dresses on its ... to all global consumers. The company’s development manager believes ... of ladies delighted. The current special offer will last ...
(Date:9/17/2014)... global ablation technologies market is estimated to grow at ... mature markets (such as the U.S., Germany, France, and ... market in 2014, the Asia-Pacific region is poised to ... next five years.Factors such as increasing government initiatives for ... surgical centers, and the rising focus of international and ...
(Date:9/17/2014)... 18, 2014 IntimateRider, an inventor of ... , has announced that it has entered into a ... Mobility LLC. A primary reason for the deal is ... reach is global. About its sales potential, representatives at ... provide you with the latest products on the market ...
(Date:9/17/2014)... 2014 According to Centers for ... an estimated 173,285 sports- and recreation-related traumatic brain injuries, ... a blood test may be available to help doctors ... recovery will take. , In March of this ... found a way to test blood for a protein ...
Breaking Medicine News(10 mins):Health News:NewsWatch Recently Featured the Fashion-Forward Frames “Francis Drake Eyewear” on National Television 2Health News:Discounted Maternity Wedding Dresses For 2014 Introduced By 9Lover.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 2Health News:IntimateRider Announces All Terrain Medical & Mobility as Its New Dealer 3Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3
... , , , SAN FRANCISCO, ... (ALCMI) today announced the execution of a letter of intent (LOI) ... on molecular diagnostic testing and banking of advanced-stage Lung Cancer tissues. ... http://www.newscom.com/cgi-bin/prnh/20090731/DC55399LOGO ) , , Specific ...
... Survivors of the childhood cancer neuroblastoma are eight times ... to be married, and more likely to have lower ... online July 31 in the Journal of the ... because minimal information exists on the long-term outcomes for ...
... , , TITUSVILLE, N.J., ... approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the ... the first once-monthly, long-acting, injectable atypical antipsychotic approved in the ... will market INVEGA SUSTENNA in the U.S. , , ...
... cells or other health conditions are spread, study finds , ... for low-risk cardiac surgery doesn,t appear to increase one,s chances ... , In the study of 1,062 people who required a ... than 80 percent of the patients were still alive a ...
... , GAINESVILLE, Fla., July 31 Sanofi-aventis US ... facial wrinkles in healthy patients in the USA. It offers results ... 7 years of experience with the product while abroad. It was ... Sanofi-aventis is a leading global pharmaceutical company. The FDA approval ...
... , , PHILADELPHIA, July 31 In ... middle class families still won,t be shielded from the crushing burden of ... erode, according to a study published this week in the New ... and David Grande, M.D., M.P.A, of the University of Pennsylvania,s ...
Cached Medicine News:Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 2Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 3Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 4Health News:Long-term health and social outcomes for neuroblastoma survivors 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 3Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 4Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 5Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 6Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 7Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 8Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 9Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 2Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 3Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 4
(Date:9/17/2014)... N.J. , Sept. 17, 2014  Bayer HealthCare ... National Hemophilia Foundation,s 66 th Annual Meeting, which ... , D.C.  The data, which will be shared through ... treatment and patient care. Data will be presented in ... research into treatment modalities in hemophilia A patients, Bayer ...
(Date:9/17/2014)... EMERYVILLE, Calif. , Sept. 17, 2014 /PRNewswire/ ... newest data analytics solution that brings complete visibility ... minimize risks in an ever-evolving reimbursement landscape. Powered ... Integrity brings transparency to the critical point between ... operations impact revenue. The solution will improve revenue ...
(Date:9/17/2014)... 2014 Women everywhere know how frustrating a ... uncomfortable, they,re often also embarrassing and have a way ... Support ( http://ph-defense.com ) is a new, over-the-counter product ... homeopathic product. Odor, discharge, and discomfort ... infection. In many cases, the cause of such problems ...
Breaking Medicine Technology:Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 2MedeAnalytics Unveils New Revenue Integrity Solution to Support the Transition to Value-Based Healthcare 3New Product from Vireo Systems: pH-D Feminine Health Support 2
... 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... to reprise key carfilzomib data presentations that were featured at ... San Diego, California. The teleconference will begin at ... Interested parties may access the teleconference and the presentation that ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, responded today to the allegations raised ... dated December 6, 2011. The Company maintains that the ... "Report") concern matters which have long been disclosed in ...
Cached Medicine Technology:China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 2China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 3China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 4China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 5China Medical Technologies Responds to the Allegations Raised by Glaucus Research Group 6
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: